全文获取类型
收费全文 | 3241篇 |
免费 | 208篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 35篇 |
妇产科学 | 35篇 |
基础医学 | 430篇 |
口腔科学 | 70篇 |
临床医学 | 247篇 |
内科学 | 642篇 |
皮肤病学 | 172篇 |
神经病学 | 259篇 |
特种医学 | 84篇 |
外科学 | 380篇 |
综合类 | 126篇 |
预防医学 | 226篇 |
眼科学 | 67篇 |
药学 | 325篇 |
1篇 | |
中国医学 | 49篇 |
肿瘤学 | 347篇 |
出版年
2023年 | 13篇 |
2022年 | 69篇 |
2021年 | 103篇 |
2020年 | 51篇 |
2019年 | 66篇 |
2018年 | 81篇 |
2017年 | 83篇 |
2016年 | 98篇 |
2015年 | 111篇 |
2014年 | 155篇 |
2013年 | 163篇 |
2012年 | 247篇 |
2011年 | 221篇 |
2010年 | 131篇 |
2009年 | 102篇 |
2008年 | 174篇 |
2007年 | 176篇 |
2006年 | 137篇 |
2005年 | 174篇 |
2004年 | 151篇 |
2003年 | 125篇 |
2002年 | 117篇 |
2001年 | 93篇 |
2000年 | 69篇 |
1999年 | 60篇 |
1998年 | 20篇 |
1997年 | 21篇 |
1996年 | 12篇 |
1995年 | 16篇 |
1994年 | 19篇 |
1993年 | 11篇 |
1992年 | 41篇 |
1991年 | 32篇 |
1990年 | 23篇 |
1989年 | 19篇 |
1988年 | 32篇 |
1987年 | 27篇 |
1986年 | 19篇 |
1985年 | 15篇 |
1983年 | 11篇 |
1982年 | 10篇 |
1980年 | 10篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1973年 | 10篇 |
1972年 | 22篇 |
1970年 | 16篇 |
1969年 | 10篇 |
1968年 | 11篇 |
1967年 | 11篇 |
排序方式: 共有3508条查询结果,搜索用时 0 毫秒
1.
Frank Lindseth Thomas Lang? Jon Bang Toril A Nagelhus Hernes 《Computer aided surgery》2002,7(4):197-222
2.
3.
Palmar advancement flap with V-Y closure for thumb tip injuries 总被引:1,自引:0,他引:1
Hwang-hyun Bang MD Tadao Kojima MD Hiroyuki Hayashi MD 《The Journal of hand surgery》1992,17(5):933-934
The palmar advancement flap with V-Y closure was used in two patients with thumb tip injuries. This technique allows more distal advancement of the flap than does a conventional palmar advancement flap and does not require skin graft coverage. 相似文献
4.
Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. 总被引:5,自引:0,他引:5
BACKGROUND. Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease. METHODS AND RESULTS. Plasminogen-activator inhibitor type 1 (PAI-1) in plasma was measured with an assay employing a specific monoclonal antibody in 40 consecutive children hospitalized with the hemolytic uremic syndrome: 12 who recovered adequate renal function (serum creatinine, less than or equal to 2.0 mg per deciliter [177 mumol per liter]) without dialysis, 23 who recovered adequate renal function after peritoneal dialysis, and 5 who did not recover adequate renal function after undergoing dialysis. At presentation, plasma PAI-1 levels were higher in the patients with the hemolytic uremic syndrome than in nine children with other forms of acute renal failure. That the inhibitor was PAI-1 was indicated by the fact that it was a potent inhibitor of tissue plasminogen activator, was acid-resistant, and was not inhibited by denaturation (all unique traits of PAI-1) and that it was neutralized by an antibody specific for PAI-1. Multivariate discriminant-function analysis revealed that the duration of elevated PAI-1 activity was strongly correlated with the outcome of the disease (P less than 0.001). Peritoneal dialysis reduced plasma PAI-1 levels dramatically. CONCLUSIONS. Our studies suggest that PAI-1 is the circulating inhibitor of fibrinolysis in the hemolytic uremic syndrome. Normalization of plasma PAI-1 levels (e.g., by peritoneal dialysis) is correlated with improvement in renal function. However, the possibility that increased plasma levels of PAI-1 are either causes or effects of the hemolytic uremic syndrome is not unequivocally established by these studies. 相似文献
5.
Bum Soon Choi Mi Jung Shin Suk Joon Shin Young Soo Kim Yeong Jin Choi Yong-Soo Kim In Sung Moon Suk Young Kim Yong Bok Koh Byung Kee Bang Chul Woo Yang 《American journal of transplantation》2005,5(6):1354-1360
We report here our 10-year experience of a biopsy performed at day 14 after transplantation in 304 patients with stable graft function. The factors that may have influenced subclinical rejection were analyzed according to histology. The incidence of subclinical rejection was 13.2%. Addition of mycophenolate mofetile (MMF) as a primary immunosuppressant significantly decreased the incidence of subclinical rejection compared with patients without such treatment (odds ratio, 0.23; p < 0.05). On the other hand, HLA-DR antigen mismatch (odds ratio, 2.39) and unrelated donor (odds ratio, 2.10) were also significantly associated with decreased subclinical rejection (p < 0.05). The incidence of acute rejection in patients with normal findings was lower than in those with borderline changes or subclinical rejection (0.23 +/- 0.05 vs. 0.48 +/- 0.07 and 0.60 +/- 0.11, respectively; p < 0.05). The graft survival rates in patients with subclinical rejection were lower than in patients with normal or borderline changes at 1 (88.4% vs. 97.9% and 99.1%; p < 0.05), 5 (77.8% vs. 96.2% and 95.9%; p < 0.05) and 10 (62.3% vs. 96.2% and 93.7%; p < 0.05) years. Thus, a protocol biopsy performed on day 14 after transplantation is useful for predicting graft survival. Triple therapy including MMF, related donor and HLA-DR antigen match are important factors for reducing subclinical rejection in living-donor renal transplantation. 相似文献
6.
7.
The effects on primary haemostasis of unfractionated heparin and of the two low molecular weight heparins, enoxaparin and fragmin, were compared in two rat models, one employing the gastric mucosa and the other the tail skin. All three heparin preparations prolonged the bleeding time and increased the blood loss dose dependently. The prolongation of the bleeding time per unit dose caused by unfractionated heparin was significantly greater than the prolongation caused by either one of the two low molecular weight heparins. In the gastric mucosa, but not in the tail skin, enoxaparin prolonged the bleeding time significantly less than fragmin (p less than 0.05). 相似文献
8.
Pathogenetical factors possibly responsible for recurrence of nontoxic goitre in a nonendemic area are evaluated. A group of 22 female patients admitted for surgical treatment of recurrent nontoxic goitre was compared with a control group of 86 female nontoxic goitrous patients not operated upon before. Preoperative serum baseline thyrotrophin levels in the recurrent goitre group were low normal and did not differ significantly from those in the control group. Circulating thyroid microsomal autoantibodies, thyroglobulin antibody titers, and the densities of lymphocytic aggregation in goitrous tissue did not differ significantly in the two groups. Thus, none of the parameters studied were likely explanations of regrowth of goitre. 相似文献
9.
目的:建立PCR—ELISA法检测附受体RNA。方法:提取20例银屑病病人和20例正常对照组血液单个核细胞标本中的总RNA,用双标记的PAF—R(Biotion与Digoxin标记)及β-actin(Biotin或Fluorescein标记)引物进行RT-PCR,用ELISA检测PCR产物,用传统的琼脂糖凝胶电泳对照。结果;ELISA法和琼脂糖凝胶电泳法对β-actin检测结果均为阳性;ELISA法检测PAF-R,20例病人标本均为阳性,20例对照组16例阳性;琼脂糖凝胶电泳法检测PAF—R,20例病人标本18例阳性,20例对照组16例阳性。结论:PCR-ELISA引物双标记法检测PAF—R操作简单,有较高的敏感性。 相似文献
10.
Kim MS Seo KS Seong HS Cho SH Lee HB Hong KD Kim SK Khang G 《Bio-medical materials and engineering》2005,15(3):229-238
p-Carboxyphenoxy propane (CPP) prepolymer consisting of 4 units and sebacic acid (SA) prepolymer consisting of about 10 units were synthesized by reacting CPP and SA in the presence of excess acetic anhydride, respectively. Polyanhydride, poly(CPP-SA) copolymers were copolymerized by a melt polycondensation process with a mixture of CPP and SA prepolymer. Copolymers of average molecular weight up to 110,000 g/mol were achieved. The crystallinity of poly(CPP-SA) copolymers was decreased by the addition of the CPP homopolymer segment to SA homopolymer. Poly(CPP-SA) copolymers gradually degraded for period of 10 days. No large difference of weight loss observed according to molecular weight variation of poly(CPP-SA) copolymers. BCNU release from wafers fabricated by poly(CPP-SA) showed a sustained release pattern with no initial burst and delay of drug release. 相似文献